This study will test the effectiveness of two drugs-nortriptyline and MS Contin (a type of
morphine)-to treat pain caused by lumbar radiculopathy, or sciatica. Sciatica results from
damage to the lumbar nerve roots, typically causing back pain and sharp, shooting pain down
one or both legs. Although sciatica is common, there are no good treatments for it. Tricyclic
antidepressants, such as nortriptyline, and opioids, such as morphine, have been effective in
treating other kinds of pain from nerve damage.
Patients between 18 and 65 years of age who have had sciatica pain daily for at least 3
months may be eligible for this study.
Participants will provide a medical history and occupational and other social information.
They will undergo a neurological examination, routine blood tests and an electrocardiogram
and will fill out three questionnaires providing information on daily functioning and
psychological well-being.
This "cross-over" study consists of several parts, including a baseline study and four
different treatment regimens. During each part, patients keep a daily log in which they rate
their pain, record other procedures they undergo, such as injections and manipulations, and
record medication side effects.
In the first week of the study, patients remain on their current medications. Any
antidepressants or opioids are stopped gradually before starting the drug trials. After the
first week, patients go through the following four drug trials in random order:
1. Nortriptyline and inert placebo-Patients take nortriptyline in doses ranging from 25 mg.
to 100 mg. and an inert placebo for morphine. (An inert placebo is a dummy pill; it
looks like the test drug but has no active ingredient.)
2. MS Contin (morphine) and inert placebo-Patients take MS Contin in doses ranging from 30
mg. to 90 mg. and an inert placebo for nortriptyline.
3. Nortriptyline and MS Contin-Patients take MS Contin and nortriptyline in the same dose
ranges as for each drug alone.
4. Active placebo and inactive placebo-Patients take an active placebo-in this case
benztropine-and an inert placebo. An active placebo is a drug that does not work for the
problem being studied but whose side effects are like those of the test drug-in this
case, slight sleepiness or dry mouth. Benztropine is given at one-third the recommended
dosage.
For each drug regimen, the medication dose is increased gradually over 5 weeks until the
maximum tolerated dose is reached. At the end of each regimen, patients are taken off the
study drugs over a 12-day tapering period and are off drugs completely for another 2 days.
Patients are seen by a doctor or nurse at the 7-week point in each study period. After all
the drug trials are finished, patients repeat the questionnaires they filled out at the
beginning of the study. Patients and their doctors will be informed of the medications that
were effective in each individual's care.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Dental and Craniofacial Research (NIDCR)